Pancreatic cancer therapy with paclitaxel

Pancreatic cancer, including cancers that are difficult to treat. It is seen from at least the development of effective chemotherapeutic drugs for cancers. Gemcitabine is the standard therapy and has been recommended. The problem is, after progression with gemcitabine achieved, not many treatment options is recommended, even NCCN recommends to get therapy clinical trials are being conducted. In addition, the choice of second-line therapy, ie capecitabine, 5-fluorouracil/leucovorin/oxaliplatin, or a combination regimen of capecitabine / oxaliplatin.

A retrospective study conducted recently on 30 the subject of people with pancreatic cancer in order to assess the benefits and tolerability of weekly cycles of paclitaxel as second-line therapy for patients with pancreatic cancer refractory to gemcitabine. Paclitaxel administered in doses of 80 mg/m2 per week (for 3